MCID: ANL017
MIFTS: 46

Anal Squamous Cell Carcinoma malady

Categories: Gastrointestinal diseases, Cancer diseases, Skin diseases

Aliases & Classifications for Anal Squamous Cell Carcinoma

Aliases & Descriptions for Anal Squamous Cell Carcinoma:

Name: Anal Squamous Cell Carcinoma 12 14 69
Epidermoid Anal Carcinoma 12
Carcinoma of Anal Margin 69

Classifications:



External Ids:

Disease Ontology 12 DOID:5525
NCIt 47 C9161
SNOMED-CT 64 255084004
UMLS 69 C1412036

Summaries for Anal Squamous Cell Carcinoma

Disease Ontology : 12 An anal carcinoma that arises near the squamocolumnar junction.

MalaCards based summary : Anal Squamous Cell Carcinoma, also known as epidermoid anal carcinoma, is related to squamous cell carcinoma and clear cell adenofibroma. An important gene associated with Anal Squamous Cell Carcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Cell Cycle, Mitotic and Glioma. The drugs Imiquimod and Immunoglobulins have been mentioned in the context of this disorder. Affiliated tissues include t cells, colon and lymph node, and related phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and endocrine/exocrine gland

Related Diseases for Anal Squamous Cell Carcinoma

Diseases related to Anal Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 145)
id Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 10.7
2 clear cell adenofibroma 10.3 CDKN2A TP53
3 lacrimal gland adenoid cystic carcinoma 10.3 CDKN2A TP53
4 pericardium leiomyoma 10.3 CDKN2A TP53
5 spondylarthropathy 10.3 CDKN2A TP53
6 lacrimal gland squamous cell carcinoma 10.3 CDKN2A TP53
7 ampulla of vater neoplasm 10.3 CDKN2A TP53
8 coccidiosis 10.3 CDKN2A TP53
9 postpoliomyelitis syndrome 10.2 CDKN2A TP53
10 paraphimosis 10.2 CDKN2A TP53
11 anal carcinoma in situ 10.2 CDKN2A TP53
12 oro-mandibular-limb hypogenesis syndrome 10.2 CDKN2A TP53
13 brain stem medulloblastoma 10.2 CDKN2A TP53
14 uterine disease 10.2 CDKN2A TP53
15 mitochondrial neurogastrointestinal encephalopathy disease 10.2 APC TP53
16 fragile x-associated tremor/ataxia syndrome 10.2 CDKN2A TP53
17 spastic ataxia 5 10.2 CDKN2A TP53
18 infantile thalamic degeneration 10.2 APC TP53
19 gallbladder pleomorphic giant cell adenocarcinoma 10.2 CDKN2A TP53
20 adult epithelioid sarcoma 10.2 CDKN2A TP53
21 uterine cervix leukoplakia 10.2 CDKN2A TP53
22 acquired hemangioma 10.2 CDKN2A TP53
23 htr2a-related altered drug metabolism 10.2 APC MLH1
24 hereditary sensory and autonomic neuropathy with deafness and global delay 10.2 APC MLH1
25 urethral verrucous carcinoma 10.2 CDKN2A TP53
26 aortic aneurysm 10.2 CDKN2A MDM2
27 rommen mueller sybert syndrome 10.2 MDM2 TP53
28 acute mountain sickness 10.2 MDM2 TP53
29 chronic monocytic leukemia 10.2 CDKN2A TP53
30 apocrine sweat gland neoplasm 10.2 CDKN2A MDM2
31 ossifying fibromyxoid tumor 10.2 CDKN2A TP53
32 functionless pituitary adenoma 10.2 MDM2 TP53
33 episodic ataxia 10.2 CDKN2A MDM2
34 scarlet fever 10.2 MDM2 TP53
35 thymus squamous cell carcinoma 10.2 CDKN2A TP53
36 mediastinum liposarcoma 10.2 CDKN2A MDM2
37 aicardi-goutieres syndrome 10.2 CDKN2A TP53
38 uterine corpus endometrial stromal sarcoma 10.2 MLH1 TP53
39 diabetes mellitus, noninsulin-dependent, 2 10.2 APC RASSF1
40 coronary stenosis 10.2 MDM2 TP53
41 angioma hereditary neurocutaneous 10.2 CDKN2A MGMT
42 brain stem angioblastoma 10.2 MDM2 TP53
43 clear cell ependymoma 10.2 MLH1 RASSF1
44 primary tubular proximal acidosis 10.2 CDKN2A MGMT
45 secondary hyperparathyroidism of renal origin 10.2 CDKN2A TP53
46 endodermal sinus tumor 10.1 MDM2 TP53
47 spastic paraplegia 1 10.1 MDM2 TP53
48 spinal cord oligodendroglioma 10.1 CDKN2A TP53
49 brain stem astrocytic neoplasm 10.1 MGMT TP53
50 brain oligodendroglioma 10.1 MDM2 TP53

Graphical network of the top 20 diseases related to Anal Squamous Cell Carcinoma:



Diseases related to Anal Squamous Cell Carcinoma

Symptoms & Phenotypes for Anal Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.02 MDM2 MGMT MLH1 RASSF1 TP53

MGI Mouse Phenotypes related to Anal Squamous Cell Carcinoma:

44 (show all 15)
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.1 AKT1 APC CDKN2A MDM2 MGMT MLH1
2 cellular MP:0005384 10.08 AKT1 APC CDKN2A MDM2 MLH1 RASSF1
3 homeostasis/metabolism MP:0005376 10.08 TP53 AKT1 APC CDKN2A MDM2 MGMT
4 cardiovascular system MP:0005385 10.02 CDKN2A MDM2 RASSF1 TP53 AKT1 APC
5 mortality/aging MP:0010768 10.01 AKT1 APC CDKN2A MDM2 MGMT MLH1
6 digestive/alimentary MP:0005381 10 APC CDKN2A MDM2 MLH1 RASSF1 TP53
7 integument MP:0010771 9.93 AKT1 APC CDKN2A MDM2 MLH1 TP53
8 neoplasm MP:0002006 9.92 RASSF1 TP53 AKT1 APC CDKN2A MDM2
9 embryo MP:0005380 9.91 AKT1 APC CDKN2A MDM2 TP53
10 liver/biliary system MP:0005370 9.91 AKT1 APC CDKN2A MDM2 RASSF1 TP53
11 muscle MP:0005369 9.77 AKT1 APC CDKN2A MDM2 TP53
12 no phenotypic analysis MP:0003012 9.65 APC CDKN2A MDM2 MGMT TP53
13 pigmentation MP:0001186 9.46 APC CDKN2A MDM2 TP53
14 reproductive system MP:0005389 9.43 AKT1 APC CDKN2A MDM2 MLH1 TP53
15 respiratory system MP:0005388 9.02 AKT1 CDKN2A MGMT MLH1 TP53

Drugs & Therapeutics for Anal Squamous Cell Carcinoma

Drugs for Anal Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Imiquimod Approved, Investigational Phase 4,Phase 3 99011-02-6 57469
2 Immunoglobulins Phase 4,Phase 2,Phase 1
3 Antibodies Phase 4,Phase 2,Phase 1
4 Adjuvants, Immunologic Phase 4,Phase 3,Phase 1
5 Vaccines Phase 4,Phase 1
6 interferons Phase 4,Phase 3
7 Interferon Inducers Phase 4,Phase 3
8
Cisplatin Approved Phase 3,Phase 2 15663-27-1 84093 441203 2767
9
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
10
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
11
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
13 Mitomycins Phase 3,Phase 2,Phase 1,Early Phase 1
14 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
15 Liver Extracts Phase 3,Phase 2,Phase 1
16 Antimetabolites Phase 3,Phase 2,Early Phase 1
17 Antimetabolites, Antineoplastic Phase 3,Phase 2,Early Phase 1
18 pancreatic polypeptide Phase 3
19 Analgesics Phase 3
20 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
21 Adjuvants, Anesthesia Phase 3
22 Narcotics Phase 3
23 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
24 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Early Phase 1
25 Analgesics, Opioid Phase 3
26 Anesthetics Phase 3
27 Anesthetics, General Phase 3
28 Anesthetics, Intravenous Phase 3
29 Peripheral Nervous System Agents Phase 3,Phase 2
30 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1
31 Antibiotics, Antitubercular Phase 3,Phase 2,Early Phase 1
32 Antimitotic Agents Phase 3,Phase 2,Phase 1
33 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
34 Central Nervous System Depressants Phase 3
35 Cola Nutraceutical Phase 3,Phase 2,Phase 1
36
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
37
Indinavir Approved Phase 2 150378-17-9 5362440
38
Cetuximab Approved Phase 2,Phase 1 205923-56-4 56842117 2333
39
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
40
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599, 9887054 43805
41
Succinylcholine Approved Phase 2 306-40-1 5314
42
Pembrolizumab Approved Phase 2 1374853-91-4
43
Daratumumab Approved Phase 1, Phase 2 945721-28-8
44
nivolumab Approved Phase 1, Phase 2 946414-94-4
45
Docetaxel Approved May 1996, Investigational Phase 2,Phase 1 114977-28-5 148124 9877265
46
protease inhibitors Phase 2
47 HIV Protease Inhibitors Phase 2
48 Cytochrome P-450 CYP3A Inhibitors Phase 2
49 Cytochrome P-450 Enzyme Inhibitors Phase 2
50 Anti-HIV Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 65)
id Name Status NCT ID Phase
1 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Active, not recruiting NCT02624349 Phase 4
2 HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions Not yet recruiting NCT03051516 Phase 4
3 Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV Withdrawn NCT01663558 Phase 4
4 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Unknown status NCT00003652 Phase 3
5 Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Completed NCT00003596 Phase 3
6 Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer Completed NCT00025090 Phase 3
7 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
8 Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy Recruiting NCT02369939 Phase 3
9 Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions Recruiting NCT02059499 Phase 3
10 Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients Enrolling by invitation NCT02526953 Phase 3
11 Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery Not yet recruiting NCT02997553 Phase 3
12 Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer Terminated NCT00068744 Phase 2, Phase 3
13 Vectibix for the Treatment of Anal Cancer Unknown status NCT01285778 Phase 2
14 Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer Unknown status NCT00955240 Phase 2
15 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
16 Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer Completed NCT00324415 Phase 2
17 A Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal. Completed NCT01941966 Phase 2
18 Oral Rigosertib for Squamous Cell Carcinoma Completed NCT01807546 Phase 2
19 Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Completed NCT00093379 Phase 2
20 Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer Completed NCT00423293 Phase 2
21 Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery Completed NCT00331760 Phase 2
22 Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus Recruiting NCT01581840 Phase 1, Phase 2
23 Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma Recruiting NCT02402842 Phase 2
24 International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel Recruiting NCT02051868 Phase 2
25 Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection Recruiting NCT02437851 Phase 2
26 Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer Recruiting NCT02560298 Phase 2
27 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting NCT02628067 Phase 2
28 An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors Recruiting NCT02488759 Phase 1, Phase 2
29 Genetic Predictors of Benefit to Pembrolizumab Recruiting NCT02710396 Phase 2
30 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
31 Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer Active, not recruiting NCT00316888 Phase 2
32 Nivolumab in Treating Patients With Refractory Metastatic Anal Canal Cancer Active, not recruiting NCT02314169 Phase 2
33 Phase 2 Study of ADXS11-001 in Subjects With Carcinoma of the Anorectal Canal Active, not recruiting NCT02399813 Phase 2
34 Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal Terminated NCT01843452 Phase 2
35 Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers Terminated NCT01382745 Phase 2
36 A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus Withdrawn NCT02857608 Phase 2
37 A Phase 1 Study in Participants With Advanced Cancer Completed NCT01115790 Phase 1
38 Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. Completed NCT00423254 Phase 1
39 Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer Completed NCT00019110 Phase 1
40 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
41 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1
42 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1
43 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1
44 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1
45 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1
46 HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA Recruiting NCT02379520 Phase 1
47 Nivolumab and Ipilimumab in Treating Patients With HIV Associated Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Recruiting NCT02408861 Phase 1
48 Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3) Recruiting NCT03100045 Phase 1
49 Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection Active, not recruiting NCT01249443 Phase 1
50 Anal Dysplasia in Patients With Inflammatory Bowel Disease Unknown status NCT01653054

Search NIH Clinical Center for Anal Squamous Cell Carcinoma

Genetic Tests for Anal Squamous Cell Carcinoma

Anatomical Context for Anal Squamous Cell Carcinoma

MalaCards organs/tissues related to Anal Squamous Cell Carcinoma:

39
T Cells, Colon, Lymph Node, Cervix

Publications for Anal Squamous Cell Carcinoma

Articles related to Anal Squamous Cell Carcinoma:

(show top 50) (show all 73)
id Title Authors Year
1
Metastatic rectal adenocarcinoma and anal squamous cell carcinoma masquerading as vulvar lymphangioma circumscriptum. ( 27616148 )
2016
2
A combined modality therapeutic approach to metastatic anal squamous cell carcinoma with systemic chemotherapy and local therapy to sites of disease: case report and review of literature. ( 27284490 )
2016
3
A Prolapsing Pile Revealing Anal Squamous Cell Carcinoma. ( 27125703 )
2016
4
Chemoradiotherapy for anal squamous cell carcinoma. ( 27118047 )
2016
5
Anal squamous cell carcinoma in Crohn's disease. ( 27773118 )
2016
6
Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma. ( 25984929 )
2016
7
Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes. ( 27052656 )
2016
8
Genomic evolution after chemoradiotherapy in anal squamous cell carcinoma. ( 27852700 )
2016
9
A Patient with HIV-Associated Metastatic Anal Squamous Cell Carcinoma Receiving Multimodality Therapy with Curative Intent: Case Report and Review of the Literature. ( 26961789 )
2016
10
Anal Squamous Cell Carcinoma: An Infrequent Challenge in the Management of Ulcerative Colitis Under Combination Therapy. ( 26818664 )
2016
11
Grade 4 radiation dermatitis presenting with full-thickness ulcerations of the groin after radiation therapy for anal squamous cell carcinoma (SCC): An example of the "bolus effect" of radiation therapy. ( 27051789 )
2015
12
A tumor control probability model for anal squamous cell carcinoma. ( 26243680 )
2015
13
Human papillomavirus DNA load and p16(INK4a) expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy. ( 24839133 )
2015
14
Concomitant Chemoradiotherapy with Cisplatin Plus 5-Fluorouracil for Anal Squamous Cell Carcinoma. ( 25810165 )
2015
15
Anal Squamous Cell Carcinoma in African Americans with and without HIV: A Comparative Study. ( 27774311 )
2015
16
Anal squamous cell carcinoma in chronic severe perianal Crohn's disease. ( 25702309 )
2015
17
Molecular biology of anal squamous cell carcinoma: implications for future research and clinical intervention. ( 26678214 )
2015
18
Tumor-infiltrating CD8(+) T lymphocytes associated with clinical outcome in anal squamous cell carcinoma. ( 26287957 )
2015
19
Human papillomavirus in anal squamous cell carcinoma: an angel rather than a devil? ( 25987898 )
2015
20
High-sensitivity human papilloma virus genotyping reveals near universal positivity in anal squamous cell carcinoma: Different implications for vaccine prevention and prognosis. ( 25702585 )
2015
21
Anal squamous cell carcinoma: an evolution in disease and management. ( 25278699 )
2014
22
Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma. ( 24885554 )
2014
23
Prognostic value of human papillomavirus in anal squamous cell carcinoma. ( 25209946 )
2014
24
Anal squamous cell carcinoma in HIV/AIDS patients in the HAART era: Report of 8 cases and literature review. ( 26753381 )
2014
25
Atypical pelvic recurrence of anal squamous cell carcinoma: successful endoscopic ultrasound-guided fine-needle aspiration through the sigmoid colon. ( 24997718 )
2014
26
Cutaneous vulvar metastases in a patient with anal squamous cell carcinoma. ( 23617081 )
2013
27
Aggressive strategy for the treatment of synchronous metastatic anal squamous cell carcinoma. ( 23958077 )
2013
28
Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis. ( 23692961 )
2013
29
A systematic review of anal squamous cell carcinoma in inflammatory bowel disease. ( 24050823 )
2013
30
Salvage Surgery for Residual Primary and Locally Recurrent Anal Squamous Cell Carcinoma After Chemoradiotherapy in HIV-positive Individuals. ( 24242676 )
2013
31
When rectal bleeding is serious: anal squamous cell carcinoma in two intravenous cyclophosphamide treated systemic lupus erythematosus patients with human papilloma virus infection. ( 23893826 )
2013
32
Outcome of salvage surgery for anal squamous cell carcinoma. ( 23522325 )
2013
33
Systematic review of sentinel lymph node biopsy in anal squamous cell carcinoma. ( 23872032 )
2013
34
Advanced anal squamous cell carcinoma -- radiotherapy or surgery? ( 23116837 )
2012
35
Evaluation of Langerhans cells counts comparing HIV-positive and negative anal squamous cell-carcinoma patients. ( 23033134 )
2012
36
Early clinical outcomes of anal squamous cell carcinoma treated with concurrent chemoradiotherapy with 5-Fluorouracil plus mitomycin C in Japanese patients: experience at a single institution. ( 22717459 )
2012
37
Current treatment of anal squamous cell carcinoma. ( 23116582 )
2012
38
Management of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapy. ( 25031942 )
2012
39
Development of cerebral metastasis after medical and surgical treatment of anal squamous cell carcinoma. ( 23091760 )
2012
40
Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinoma. ( 21291546 )
2011
41
The role of A^a8,fluoro-deoxy glucose combined position emission and computed tomography in the clinical management of anal squamous cell carcinoma. ( 20070338 )
2011
42
The prognostic significance of tumor human papillomavirus status for patients with anal squamous cell carcinoma treated with combined chemoradiotherapy. ( 21128253 )
2011
43
Metachronous splenic metastasis in an anal squamous cell carcinoma. ( 21563664 )
2011
44
Chemoradiation for anal squamous cell carcinoma: case report. ( 22018257 )
2011
45
Radiation therapy of recurrent anal squamous cell carcinoma in-situ: a case report. ( 20181236 )
2010
46
Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978-2005. ( 19960431 )
2010
47
Current therapeutic strategies for anal squamous cell carcinoma in Japan. ( 19856049 )
2009
48
Anal squamous cell carcinoma in the HIV-positive patient. ( 20436834 )
2009
49
Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma. ( 19330178 )
2009
50
Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy. ( 18066626 )
2008

Variations for Anal Squamous Cell Carcinoma

Expression for Anal Squamous Cell Carcinoma

Search GEO for disease gene expression data for Anal Squamous Cell Carcinoma.

Pathways for Anal Squamous Cell Carcinoma

Pathways related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.25 AKT1 CDKN2A MDM2 MLH1 TP53
2
Show member pathways
12.86 AKT1 APC CDKN2A MDM2 RASSF1 TP53
3
Show member pathways
12.84 AKT1 CDKN2A MDM2 MLH1 TP53
4
Show member pathways
12.66 AKT1 CDKN2A MDM2 TP53
5
Show member pathways
12.46 AKT1 CDKN2A MDM2 TP53
6 12.38 APC CDKN2A MDM2 RASSF1 TP53
7 12.36 CDKN2A MDM2 MGMT MLH1 TP53
8 12.34 AKT1 APC CDKN2A TP53
9
Show member pathways
12.3 AKT1 MDM2 TP53
10 12.3 AKT1 APC CDKN2A MDM2 MLH1 RASSF1
11 12.28 AKT1 APC TP53
12 12.27 APC CDKN2A MDM2 TP53
13
Show member pathways
12.26 AKT1 MDM2 TP53
14
Show member pathways
12.23 CDKN2A MDM2 TP53
15
Show member pathways
12.18 AKT1 MDM2 TP53
16
Show member pathways
12.18 AKT1 APC MDM2 MLH1 TP53
17 12.17 AKT1 MDM2 TP53
18 12.16 AKT1 MDM2 TP53
19 12.16 CDKN2A MDM2 TP53
20
Show member pathways
12.12 AKT1 MDM2 TP53
21 12.11 AKT1 APC MLH1 TP53
22
Show member pathways
12.05 AKT1 MDM2 TP53
23 12.02 AKT1 MDM2 TP53
24
Show member pathways
12.01 AKT1 CDKN2A MDM2 TP53
25 11.98 AKT1 MDM2 TP53
26 11.98 APC MDM2 MLH1 TP53
27 11.89 AKT1 MDM2 TP53
28 11.84 CDKN2A MDM2 TP53
29 11.78 AKT1 APC CDKN2A MDM2 TP53
30 11.72 AKT1 MDM2 TP53
31 11.64 CDKN2A MDM2 RASSF1 TP53
32
Show member pathways
11.62 AKT1 CDKN2A MDM2 TP53
33 11.57 CDKN2A MDM2 TP53
34 11.56 AKT1 CDKN2A MDM2 MGMT MLH1 TP53
35 11.53 CDKN2A MDM2 TP53
36
Show member pathways
11.52 AKT1 MDM2 TP53
37 11.52 AKT1 CDKN2A MDM2 MLH1 TP53
38 11.48 AKT1 MDM2 RASSF1 TP53
39 11.44 AKT1 MDM2 TP53
40 11.4 AKT1 APC MDM2 TP53
41
Show member pathways
11.37 AKT1 TP53
42
Show member pathways
11.37 AKT1 TP53
43
Show member pathways
11.36 MGMT MLH1
44 11.35 MDM2 TP53
45 11.34 AKT1 APC
46
Show member pathways
11.3 MLH1 TP53
47 11.27 APC TP53
48 11.27 CDKN2A MDM2 TP53
49 11.24 AKT1 MDM2 TP53
50 11.17 AKT1 APC

GO Terms for Anal Squamous Cell Carcinoma

Cellular components related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.56 AKT1 APC CDKN2A MDM2 MGMT MLH1
2 nucleoplasm GO:0005654 9.17 AKT1 APC CDKN2A MDM2 MGMT MLH1

Biological processes related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 22)
id Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 9.87 CDKN2A MLH1 RASSF1 TP53
2 negative regulation of apoptotic process GO:0043066 9.81 AKT1 MDM2 MGMT TP53
3 protein deubiquitination GO:0016579 9.78 APC MDM2 TP53
4 positive regulation of apoptotic process GO:0043065 9.67 AKT1 APC CDKN2A TP53
5 regulation of signal transduction by p53 class mediator GO:1901796 9.65 AKT1 MDM2 TP53
6 protein complex assembly GO:0006461 9.63 APC MDM2 TP53
7 protein destabilization GO:0031648 9.6 CDKN2A MDM2
8 execution phase of apoptosis GO:0097194 9.59 AKT1 APC
9 response to antibiotic GO:0046677 9.58 MDM2 TP53
10 cellular response to ionizing radiation GO:0071479 9.58 MGMT TP53
11 cellular response to hypoxia GO:0071456 9.58 AKT1 MDM2 TP53
12 cellular response to gamma radiation GO:0071480 9.56 MDM2 TP53
13 apoptotic mitochondrial changes GO:0008637 9.55 AKT1 CDKN2A
14 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.54 APC CDKN2A
15 positive regulation of protein export from nucleus GO:0046827 9.52 MDM2 TP53
16 cellular response to organic cyclic compound GO:0071407 9.5 AKT1 MDM2 MGMT
17 mammary gland epithelial cell differentiation GO:0060644 9.49 AKT1 MGMT
18 replicative senescence GO:0090399 9.43 CDKN2A TP53
19 Ras protein signal transduction GO:0007265 9.43 CDKN2A RASSF1 TP53
20 cellular response to DNA damage stimulus GO:0006974 9.35 AKT1 APC MGMT MLH1 TP53
21 cellular response to actinomycin D GO:0072717 9.16 MDM2 TP53
22 cell cycle arrest GO:0007050 8.92 APC CDKN2A RASSF1 TP53

Molecular functions related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.62 AKT1 APC MDM2 TP53
2 disordered domain specific binding GO:0097718 9.26 MDM2 TP53
3 protein phosphatase 2A binding GO:0051721 9.16 AKT1 TP53
4 SUMO transferase activity GO:0019789 8.96 CDKN2A MDM2
5 protein kinase binding GO:0019901 8.92 AKT1 APC CDKN2A TP53

Sources for Anal Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....